Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Inventory: 2022-2024

Historic Inventory for Gyre Therapeutics (GYRE) over the last 3 years, with Dec 2024 value amounting to $6.3 million.

  • Gyre Therapeutics' Inventory rose 38.80% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 38.80%. This contributed to the annual value of $6.3 million for FY2024, which is 48.03% up from last year.
  • Per Gyre Therapeutics' latest filing, its Inventory stood at $6.3 million for FY2024, which was up 48.03% from $4.3 million recorded in FY2023.
  • Gyre Therapeutics' 5-year Inventory high stood at $6.3 million for FY2024, and its period low was $4.3 million during FY2023.
  • Its 3-year average for Inventory is $5.6 million, with a median of $6.1 million in 2022.
  • Per our database at Business Quant, Gyre Therapeutics' Inventory plummeted by 30.07% in 2023 and then skyrocketed by 48.03% in 2024.
  • Yearly analysis of 3 years shows Gyre Therapeutics' Inventory stood at $6.1 million in 2022, then slumped by 30.07% to $4.3 million in 2023, then skyrocketed by 48.03% to $6.3 million in 2024.